{"success":true,"data":{"pressRelease":{"id":"163327","rtpr_id":"nGNX4DqCxP-20261007","ticker":"XENE","exchange":"NASDAQ","all_tickers":["XENE"],"title":"Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors","author":"Globe Newswire","published_at":"2026-10-07T14:30:31.090Z","article_body":"NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP continues to\ninvestigate potential claims on behalf of purchasers of Xenon Pharmaceuticals\nInc. (“Xenon”) common stock (NASDAQ: XENE).\n\nXenon is a clinical-stage drug company developing azetukalner (formerly\nXEN1101), its lead drug candidate, for neurological and psychiatric disorders,\nprincipally focal-onset seizures, major depressive disorder (MDD), and bipolar\ndepression. Azetukalner is a selective Kv7 potassium-channel opener designed\nto reduce excessive neuronal activity in the brain. In January 2025, Xenon\nannounced the initiation of its Phase 3 X-NOVA2 trial, designed to enroll\napproximately 450 patients to evaluate a 20-mg dose of azetukalner against\nplacebo for the treatment of MDD.\n\nAfter the market closed on September 17, 2026, Xenon announced a voluntary\npause in new patient enrollment in its ongoing clinical studies in MDD and\nbipolar depression following an analysis of neuropsychiatric adverse events in\nthose studies. Following this announcement, Xenon’s stock price fell $17.60\nper share, or 30.7%, to close at $39.75 on September 18, 2026, on very heavy\ntrading volume.\n\nInvestors who suffered losses trading Xenon common stock and would like to\ndiscuss the investigation are encouraged to contact Adam Savett at (212)\n451-9655 or asavett@wolfpopper.com.\n\nWolf Popper has recovered billions of dollars for defrauded investors. Courts\nhave repeatedly recognized the firm’s reputation and expertise by appointing\nit to major roles in securities litigation. For more information about Wolf\nPopper, please visit www.wolfpopper.com.\n\nMay Be Considered Attorney Advertising in Certain Jurisdictions. \nPrior Results Do Not Guarantee a Similar Outcome.\n\nWolf Popper LLP\nAdam Savett, Esq.\n570 Lexington Avenue\nNew York, NY 10022\nTel.: (212) 451-9655\nEmail: asavett@wolfpopper.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/56b8a498-8284-4741-b289-b6480363251c)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX4DqCxP-20261007","title":"Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors","author":"Globe Newswire","ticker":"XENE","created":"2026-10-07T14:30:31.090Z","tickers":["XENE"],"exchange":"NASDAQ","article_body":"NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP continues to\ninvestigate potential claims on behalf of purchasers of Xenon Pharmaceuticals\nInc. (“Xenon”) common stock (NASDAQ: XENE).\n\nXenon is a clinical-stage drug company developing azetukalner (formerly\nXEN1101), its lead drug candidate, for neurological and psychiatric disorders,\nprincipally focal-onset seizures, major depressive disorder (MDD), and bipolar\ndepression. Azetukalner is a selective Kv7 potassium-channel opener designed\nto reduce excessive neuronal activity in the brain. In January 2025, Xenon\nannounced the initiation of its Phase 3 X-NOVA2 trial, designed to enroll\napproximately 450 patients to evaluate a 20-mg dose of azetukalner against\nplacebo for the treatment of MDD.\n\nAfter the market closed on September 17, 2026, Xenon announced a voluntary\npause in new patient enrollment in its ongoing clinical studies in MDD and\nbipolar depression following an analysis of neuropsychiatric adverse events in\nthose studies. Following this announcement, Xenon’s stock price fell $17.60\nper share, or 30.7%, to close at $39.75 on September 18, 2026, on very heavy\ntrading volume.\n\nInvestors who suffered losses trading Xenon common stock and would like to\ndiscuss the investigation are encouraged to contact Adam Savett at (212)\n451-9655 or asavett@wolfpopper.com.\n\nWolf Popper has recovered billions of dollars for defrauded investors. Courts\nhave repeatedly recognized the firm’s reputation and expertise by appointing\nit to major roles in securities litigation. For more information about Wolf\nPopper, please visit www.wolfpopper.com.\n\nMay Be Considered Attorney Advertising in Certain Jurisdictions. \nPrior Results Do Not Guarantee a Similar Outcome.\n\nWolf Popper LLP\nAdam Savett, Esq.\n570 Lexington Avenue\nNew York, NY 10022\nTel.: (212) 451-9655\nEmail: asavett@wolfpopper.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/56b8a498-8284-4741-b289-b6480363251c)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-07T14:30:31.13278445Z","server_sent_at_ms":1791383431132},"received_at":"2026-10-07T14:30:31.184Z","source_url":null},"analysis":{"id":"151784","press_release_id":"163327","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":["underlying risk: voluntary clinical-hold-style enrollment pause in azetukalner Phase 3 MDD/bipolar trials amid neuropsychiatric adverse events"],"eventType":"legal_litigation","narrative":"Wolf Popper LLP is investigating potential claims on behalf of purchasers of Xenon Pharmaceuticals (NASDAQ: XENE) common stock.\n\nThe investigation follows Xenon's September 17, 2026 disclosure of a voluntary pause in new patient enrollment in its MDD and bipolar depression studies after an analysis of neuropsychiatric adverse events; the stock fell 30.7% to $39.75 on September 18.\n\nThis release is a law-firm solicitation encouraging investors to contact counsel — it is not a new company disclosure and adds no new clinical or financial information.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation following previously disclosed clinical enrollment pause — suppress as noise."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[{"name":"Adam Savett","role":"attorney, Wolf Popper LLP"}],"products":["azetukalner (XEN1101)"],"companies":[{"name":"Wolf Popper LLP","relationship":"plaintiff law firm"},{"name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","relationship":"subject of investigation"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm investigation solicitation issued by Wolf Popper LLP. No new issuer disclosure, no certified class or settlement; the underlying enrollment-pause news was previously announced on September 17, 2026."},"tickerRelevance":{"others":[],"primary":"XENE"},"globalImportance":15,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap-biotech","eventGravity":"law-firm-solicitation","issuerAuthored":false,"priorEventRecency":"enrollment pause already disclosed Sept 17, 2026"}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Wolf Popper LLP is investigating potential claims on behalf of purchasers of Xenon Pharmaceuticals (NASDAQ: XENE) common stock.\n\nThe investigation follows Xenon's September 17, 2026 disclosure of a voluntary pause in new patient enrollment in its MDD and bipolar depression studies after an analysis of neuropsychiatric adverse events; the stock fell 30.7% to $39.75 on September 18.\n\nThis release is a law-firm solicitation encouraging investors to contact counsel — it is not a new company disclosure and adds no new clinical or financial information.","key_figures":{},"named_entities":{"people":[{"name":"Adam Savett","role":"attorney, Wolf Popper LLP"}],"products":["azetukalner (XEN1101)"],"companies":[{"name":"Wolf Popper LLP","relationship":"plaintiff law firm"},{"name":"Xenon Pharmaceuticals Inc.","ticker":"XENE","relationship":"subject of investigation"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-07T14:30:36.080Z","global_importance":15,"audience_relevance":15,"importance_components":{"tickerTier":"mid-cap-biotech","eventGravity":"law-firm-solicitation","issuerAuthored":false,"priorEventRecency":"enrollment pause already disclosed Sept 17, 2026"}},"durationMs":4965,"modelName":"glm-5.3-flashx"}}